首页|布地奈德雾化吸入联合哌拉西林他唑巴坦对慢性阻塞性肺疾病患者肺功能及炎性反应的影响

布地奈德雾化吸入联合哌拉西林他唑巴坦对慢性阻塞性肺疾病患者肺功能及炎性反应的影响

扫码查看
目的 探讨布地奈德雾化吸入联合哌拉西林他唑巴坦对慢性阻塞性肺疾病(COPD)患者肺功能及炎性反应的影响.方法 选取2021年3月至2022年3月我院收治的100例COPD患者,随机分为两组各50例.对照组采用哌拉西林他唑巴坦治疗,观察组在此基础上采用布地奈德雾化吸入治疗,治疗时间14 d.比较两组的临床疗效、肺功能指标(FEV,、FVC、PEF)及炎性因子(PCT、CRP、TNF-α).结果 观察组治疗总有效率为94.00%,高于对照组的78.00%(P<0.05).治疗后,观察组FEV1、FVC、PEF高于对照组(P<0.05).治疗后,观察组PCT、CRP、TNF-α水平低于对照组(P<0.05).结论 布地奈德雾化吸入联合哌拉西林他唑巴坦联合治疗COPD患者,可显著提高临床疗效,改善患者肺功能,减轻炎性反应,值得临床推广.
Impact of Budesonide Nebulization Inhalation Combined with Piperacillin Tazobactam on Lung Function and Inflammatory Response in Patients with Chronic Obstructive Pulmonary Disease
Objective To analyze the effect of budesonide nebulization inhalation combined with piperacillin tazobactam on lung function and inflammatory response in patients with chronic obstructive pulmonary disease(COPD).Methods 100 COPD patients admitted to our hospital from March 2021 to March 2022 were selected and randomly divided into two groups,with 50 cases in each group.The control group was treated with piperacillin tazobactam,and the observation group was treated with budesonide nebulization inhalation on this basis for 14 days.The clinical efficacy,lung function indicators(FEV1,FVC,PEF),inflammatory factors(PCT,CRP,TNF-α)were compared between the two groups.Results The total effective rate of treatment in the observation group was 94.00%,higher than 78.00%in the control group(P<0.05).After treatment,the FEV1,FVC and PEF of the observation group were higher than those of the control group(P<0.05).After treatment,the PCT,CRP,and TNF-α levels of the observation group were lower than those of the control group(P<0.05).Conclusions Budesonide nebulization inhalation combined with piperacillin tazobactam in the treatment of COPD patients can significantly improve the clinical efficacy and lung function,and reduce the inflammatory reactions,which is worthy of clinical promotion.

Chronic obstructive pulmonary diseaseBudesonidePiperacillin tazobactamLung functionInflammatory reaction

谢洪涛、尚晓军、熊贤普

展开 >

南昌市新建区人民医院呼吸内科,江西南昌 330100

慢性阻塞性肺疾病 布地奈德 哌拉西林他唑巴坦 肺功能 炎性反应

2024

临床医学工程
国家医疗保健器具工程技术研究中心

临床医学工程

影响因子:0.193
ISSN:1674-4659
年,卷(期):2024.31(5)
  • 9